Effect of N-palmitoylethanolamine-oxazoline on comorbid neuropsychiatric disturbance associated with inflammatory bowel disease

Marika Cordaro, Maria Scuto, Rosalba Siracusa, Ramona D'amico, Alessio Filippo Peritore, Enrico Gugliandolo, Roberta Fusco, Rosalia Crupi, Daniela Impellizzeri, Michele Pozzebon, Daniele Alfonsi, Nicolò Mattei, Gabriele Marcolongo, Maurizio Evangelista, Salvatore Cuzzocrea, Rosanna Di Paola. FASEB J. 2020 Mar;34(3):4085-4106.

Laboratory studyOther animalsWith PEA-OXA (a PEA analogue, tested alone)

This study tested palmitoylethanolamide together with PEA-OXA (a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design

Laboratory study

Subjects

Rats with colitis induced by oral dextran sulfate sodium; numbers not stated in the abstract

Dose used in the study

PEA-OXA 10 mg/kg daily by mouth

Duration

Not stated in the abstract

What was measured

Body weight loss, macroscopic colon damage, colon length, histology and inflammation; neurotrophic factors, astroglial and microglial activation; intestinal permeability, tight junction proteins and apoptosis in colon and brain.

What the authors reported

Daily oral PEA-OXA reduced weight loss, macroscopic damage, colon shortening, histological change and inflammation after DSS. It increased neurotrophic growth factor release, reduced astroglial and microglial activation, restored intestinal permeability and tight junctions, and reduced apoptosis in colon and brain.

Limits of this study

A rat model of colitis using a PEA analogue, not PEA itself; it cannot show effect in people. Study length and animal numbers are not given in the abstract. Conflicts not stated in the record, though this Messina group has worked with Epitech, which develops PEA-OXA.

Source

PubMed 31950563 · doi:10.1096/fj.201901584RR

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.